Sandbox Reserved 1544
From Proteopedia
(Difference between revisions)
Line 5: | Line 5: | ||
== Function == | == Function == | ||
- | The first reaction in β-oxidation, or fatty acid metabolism, is the catalyzation of the ester bond (C2 and C3) of the substrate Acyl-CoA.<ref name="Berg">Berg JM, Tymoczko JL, Stryer L. Biochemistry. 5th edition. New York: W H Freeman; 2002. Chapter 22, Fatty Acid Metabolism. Available from: https://www.ncbi.nlm.nih.gov/books/NBK21173/</ref> This is accomplished through '''Acyl-CoA Dehydrogenase (ACDH)''' and its cofactor FAD.<ref name="Berg"/> ACDH is classified according to its length of its substrates: short (SCAD), medium (MCAD), very and very long-chain (VLCAD). | + | The first reaction in β-oxidation, or fatty acid metabolism, is the catalyzation of the ester bond (C2 and C3) of the substrate Acyl-CoA.<ref name="Berg">Berg JM, Tymoczko JL, Stryer L. Biochemistry. 5th edition. New York: W H Freeman; 2002. Chapter 22, Fatty Acid Metabolism. Available from: https://www.ncbi.nlm.nih.gov/books/NBK21173/</ref> This is accomplished through '''Acyl-CoA Dehydrogenase (ACDH)''' and its cofactor FAD.<ref name="Berg"/> ACDH is classified according to its length of its substrates: short (SCAD), medium (MCAD), very and very long-chain (VLCAD).<ref name="Lee"/> |
== Disease == | == Disease == | ||
- | Medium-chain acyl-CoA dehydrogenase deficiency (MCADD) is a disorder that affects fatty acid oxidation and can be characterized by a hypoglycemic crisis during times of increased stress.<ref name="Lee">Lee, H.-J. K.; Wang, M.; Paschke, R.; Nandy, A.; Ghisla, S.; Kim, J.-J. P. Crystal Structures of the Wild Type and the Glu376Gly/Thr255Glu Mutant of Human Medium-Chain Acyl-CoA Dehydrogenase: Influence of the Location of the Catalytic Base on Substrate Specificity†. https://pubs.acs.org/doi/pdf/10.1021/bi9607867 (accessed May 5, 2019).</ref> Expression of MCADD results in a decrease of ketone production and an increase in medium-chain fatty acid concentration. MCADD is a disorder inherited genetically through an autosomal recessive trait, and it is caused by mutations in the medium-chain acyl- CoA dehydrogenase (ACADM) gene. The ACADM gene is located on chromosome 1p31. There are over 90 different ACADM gene mutations known so far, most of which are missense mutations. The disorder can lead to symptoms such as a loss in appetite as well as vomiting and diarrhea. This can result in accumulated concentrations of acylcarnitine, which can be potentially toxic. People who are affected and not diagnosed are at a high risk of dying or experiencing permanent neurological damage during their first metabolic crisis. To prevent such events, immediate care should follow catabolic stress and fasting should be averted. Individuals living with MCADD are asymptomatic up until there is an increased demand for energy followed by a prolonged time of fasting. Newborn screening is now widely implemented through the use of liquid chromatography-tandem mass spectrometry.<ref name="Lee"/> | + | Medium-chain acyl-CoA dehydrogenase deficiency (MCADD) is a disorder that affects fatty acid oxidation and can be characterized by a hypoglycemic crisis during times of increased stress.<ref name="Lee">Lee, H.-J. K.; Wang, M.; Paschke, R.; Nandy, A.; Ghisla, S.; Kim, J.-J. P. Crystal Structures of the Wild Type and the Glu376Gly/Thr255Glu Mutant of Human Medium-Chain Acyl-CoA Dehydrogenase: Influence of the Location of the Catalytic Base on Substrate Specificity†. https://pubs.acs.org/doi/pdf/10.1021/bi9607867 (accessed May 5, 2019).</ref> Expression of MCADD results in a decrease of ketone production and an increase in medium-chain fatty acid concentration.<ref name="Lee"/> MCADD is a disorder inherited genetically through an autosomal recessive trait, and it is caused by mutations in the medium-chain acyl- CoA dehydrogenase (ACADM) gene.<ref name="Lee"/> The ACADM gene is located on chromosome 1p31.<ref name="Lee"/> There are over 90 different ACADM gene mutations known so far, most of which are missense mutations.<ref name="Lee"/> The disorder can lead to symptoms such as a loss in appetite as well as vomiting and diarrhea.<ref name="Lee"/> This can result in accumulated concentrations of acylcarnitine, which can be potentially toxic.<ref name="Lee"/> People who are affected and not diagnosed are at a high risk of dying or experiencing permanent neurological damage during their first metabolic crisis.<ref name="Lee"/> To prevent such events, immediate care should follow catabolic stress and fasting should be averted.<ref name="Lee"/> Individuals living with MCADD are asymptomatic up until there is an increased demand for energy followed by a prolonged time of fasting.<ref name="Lee"/> Newborn screening is now widely implemented through the use of liquid chromatography-tandem mass spectrometry.<ref name="Lee"/> |
== Relevance == | == Relevance == | ||
'''Fatty Acid Metabolism''' | '''Fatty Acid Metabolism''' | ||
- | Acyl-CoA dehydrogenase is the first enzyme used to metabolize fatty acids. | + | Acyl-CoA dehydrogenase is the first enzyme used to metabolize fatty acids.<ref name="Berg"/> |
- | In the first step, fatty acyl-CoA is converted to trans-Δ<sup>2</sup>-enoyl-CoA via acyl-CoA dehydrogenase with the help of FAD, releasing FADH<sub>2</sub> as a byproduct. | + | In the first step, fatty acyl-CoA is converted to trans-Δ<sup>2</sup>-enoyl-CoA via acyl-CoA dehydrogenase with the help of FAD, releasing FADH<sub>2</sub> as a byproduct.<ref name="Berg"/> |
- | In the second step, trans-Δ<sup>2</sup>-enoyl-CoA is converted to 3-L-hydroxyacyl-CoA via enoyl-CoA hydratase with the help of H<sub>2</sub>O. | + | In the second step, trans-Δ<sup>2</sup>-enoyl-CoA is converted to 3-L-hydroxyacyl-CoA via enoyl-CoA hydratase with the help of H<sub>2</sub>O.<ref name="Berg"/> |
- | In the third step, 3-L-hydroxyacyl-CoA is converted to β-ketoacyl-CoA via 3-hydroxyacyl-CoA dehydrogenase with the help of NAD<sup>+</sup>, releasing NADH + H<sup>+</sup> as a byproduct. | + | In the third step, 3-L-hydroxyacyl-CoA is converted to β-ketoacyl-CoA via 3-hydroxyacyl-CoA dehydrogenase with the help of NAD<sup>+</sup>, releasing NADH + H<sup>+</sup> as a byproduct.<ref name="Berg"/> |
- | In the fourth step, β-ketoacyl-CoA is converted to another fatty acyl-CoA with two less carbons or finishes the cycle as Acetyl-CoA if there are two remaining carbons. This reaction occurs via β-ketohiolase with the help of CoA-SH. | + | In the fourth step, β-ketoacyl-CoA is converted to another fatty acyl-CoA with two less carbons or finishes the cycle as Acetyl-CoA if there are two remaining carbons.<ref name="Berg"/> This reaction occurs via β-ketohiolase with the help of CoA-SH.<ref name="Berg"/> |
- | The four steps are repeated until the fatty acid is metabolized to less than or equal to 3 carbons. | + | The four steps are repeated until the fatty acid is metabolized to less than or equal to 3 carbons.<ref name="Berg"/> |
== Structural highlights == | == Structural highlights == | ||
Line 30: | Line 30: | ||
'''Catalytic Residues''' | '''Catalytic Residues''' | ||
- | Glu255 is responsible for the catalytic activity of mutant Medium Chain Acyl-CoA Dehydrogenase (MCADH). It can be in “active” or “resting” states. It is mostly in the “resting” state, due to its ability to hydrogen bond with Glu99.<ref name="Lee"/> | + | Glu255 is responsible for the catalytic activity of mutant Medium Chain Acyl-CoA Dehydrogenase (MCADH).<ref name="Lee"/> It can be in “active” or “resting” states.<ref name="Lee"/> It is mostly in the “resting” state, due to its ability to hydrogen bond with Glu99.<ref name="Lee"/> |
- | Long Chain Acyl-CoA Dehydrogenase (LCADH) and Isovaleryl-CoA Dehydrogenase (IVDH) have a higher catalytic activity than MCADH because they have serine and glycine in their 99 position, respectively. Neither of these amino acids can form hydrogen bonds, so the Glu255 is in the “active state.” The catalytic residue of LCADH is Glu261; the catalytic residue of IVDH is Glu254.<ref name="Lee"/> | + | Long Chain Acyl-CoA Dehydrogenase (LCADH) and Isovaleryl-CoA Dehydrogenase (IVDH) have a higher catalytic activity than MCADH because they have serine and glycine in their 99 position, respectively.<ref name="Lee"/> Neither of these amino acids can form hydrogen bonds, so the Glu255 is in the “active state.”<ref name="Lee"/> The catalytic residue of LCADH is Glu261; the catalytic residue of IVDH is Glu254.<ref name="Lee"/> |
Glu376 is the amino acid responsible for catalytic activity of the wild type.<ref name="Lee"/> | Glu376 is the amino acid responsible for catalytic activity of the wild type.<ref name="Lee"/> | ||
Line 38: | Line 38: | ||
'''Significance of the Positions of Glutamate on the Wild Type (Glu376) and Mutant (Glu255)''' | '''Significance of the Positions of Glutamate on the Wild Type (Glu376) and Mutant (Glu255)''' | ||
- | The distance between the donor proton and the base that attacks the donor proton affect the catalytic activity of the carboxylate base of the glutamates. The distance between the proton and glutamates carboxylates are more than 4.0 A.<ref name="Lee"/> | + | The distance between the donor proton and the base that attacks the donor proton affect the catalytic activity of the carboxylate base of the glutamates.<ref name="Lee"/> The distance between the proton and glutamates carboxylates are more than 4.0 A.<ref name="Lee"/> |
Glu376 would conform so that its carboxylate oxygen lies close to the proton (2.4A).<ref name="Lee"/> | Glu376 would conform so that its carboxylate oxygen lies close to the proton (2.4A).<ref name="Lee"/> | ||
- | Glu255 has a smaller catalytic activity because is over 4.0 A away from the proton. It is thought that due to MCADH’s flexibility at Gly376, Glu255’s carboxylate oxygen will be closer to the donor proton.<ref name="Lee"/> | + | Glu255 has a smaller catalytic activity because is over 4.0 A away from the proton.<ref name="Lee"/> It is thought that due to MCADH’s flexibility at Gly376, Glu255’s carboxylate oxygen will be closer to the donor proton.<ref name="Lee"/> |
- | When both Glu255 and Glu376 are available to the Thr255Glu mutant, Glu376 can act as a catalytic residue and Glu255 adopts the “resting” conformation. This is expected given that the kinetic parameters of the mutant and its optimum substrates (C8- and C10-CoA) are similar to those of the wild type enzyme. The substrates (in both wild type and MLCADH) with alkyl chain lengths that are longer than C12-CoA can form multiple conformers at its ω-end in the active site cavity. However, this is not the case for the Glu/Glu mutant due to the glutamate side chains. This steric hindrance prevents the binding of the long substrate in an orientation that would allow catalysis to occur.<ref name="Lee"/> | + | When both Glu255 and Glu376 are available to the Thr255Glu mutant, Glu376 can act as a catalytic residue and Glu255 adopts the “resting” conformation.<ref name="Lee"/> This is expected given that the kinetic parameters of the mutant and its optimum substrates (C8- and C10-CoA) are similar to those of the wild type enzyme.<ref name="Lee"/> The substrates (in both wild type and MLCADH) with alkyl chain lengths that are longer than C12-CoA can form multiple conformers at its ω-end in the active site cavity.<ref name="Lee"/> However, this is not the case for the Glu/Glu mutant due to the glutamate side chains.<ref name="Lee"/> This steric hindrance prevents the binding of the long substrate in an orientation that would allow catalysis to occur.<ref name="Lee"/> |
'''Solvent Accessibility and Oxygen Reactivity.''' | '''Solvent Accessibility and Oxygen Reactivity.''' | ||
- | In the MLCADH, the bore of the active site cavity at its midsection is wider and allows the longer substrate to adopt multiple conformations at its ω-end. This better accommodates the MLCADH for catalysis than the wild type. The wider bore also allows bulkier substrates to bind to the enzyme more easily. Having a larger active site allows more solvent molecules, which leads to larger amounts of molecular oxygen, which is becomes readily available to reduced Flavin. This difference in width (8.5 Å vs 5.1 Å) allows for the oxidation of the reduced Flavin to occur somewhere between 10 to 100 times faster than the wild type. Ligands that lack the carbonyl oxygen are much less effective at protecting the reduced enzyme flavin toward molecular oxygen.<ref name="Lee"/> | + | In the MLCADH, the bore of the active site cavity at its midsection is wider and allows the longer substrate to adopt multiple conformations at its ω-end.<ref name="Lee"/> This better accommodates the MLCADH for catalysis than the wild type.<ref name="Lee"/> The wider bore also allows bulkier substrates to bind to the enzyme more easily.<ref name="Lee"/> Having a larger active site allows more solvent molecules, which leads to larger amounts of molecular oxygen, which is becomes readily available to reduced Flavin.<ref name="Lee"/> This difference in width (8.5 Å vs 5.1 Å) allows for the oxidation of the reduced Flavin to occur somewhere between 10 to 100 times faster than the wild type.<ref name="Lee"/> Ligands that lack the carbonyl oxygen are much less effective at protecting the reduced enzyme flavin toward molecular oxygen.<ref name="Lee"/> |
== References == | == References == | ||
<references/> | <references/> |
Revision as of 17:24, 6 May 2019
This Sandbox is Reserved from May 28 through July 01, 2019 for use in the course Advanced Biochemistry BCHM 4100 taught by Tom Gluick at the Georgia Gwinnett College. This reservation includes Sandbox Reserved 1544 through Sandbox Reserved 1555. |
To get started:
More help: Help:Editing |
|